Seres Therapeutics, Inc.

Seres Therapeutics is a biotechnology company pioneering a novel approach to treating disease by harnessing the power of the human microbiome. The company is focused on developing a new class of biological therapeutics designed to modulate the microbiome to improve patient outcomes. Seres' investigational therapies target a range of conditions, including inflammatory bowel disease (IBD) and other gastrointestinal disorders. By restoring a healthy microbiome composition, Seres aims to address the underlying causes of these diseases, offering potential alternatives to traditional treatments. The company's research and development efforts are centered on understanding the complex interactions between the microbiome and the human body, paving the way for innovative therapies with the potential to transform patient care within the biopharmaceutical sector.